How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey
How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey
The effects of COVID-19 have the potential to impact on the management of chronic diseases including osteoporosis. A global survey has demonstrated that these impacts include an increase in telemedicine consultations, delays in DXA scanning, interruptions in the supply of medications and reductions in parenteral medication delivery.
INTRODUCTION: The COVID-19 pandemic has had profound effects on the health of the global population both directly, via the sequelae of the infection, and indirectly, including the relative neglect of chronic disease management. Together the International Osteoporosis Foundation and National Osteoporosis Foundation sought to ascertain the impact on osteoporosis management.
METHODS: Questionnaires were electronically circulated to a sample of members of both learned bodies and included information regarding the location and specialty of respondents, current extent of face to face consultations, alterations in osteoporosis risk assessment, telemedicine experience, alterations to medication ascertainment and delivery and electronic health record (EHR) utilisation. Responses were collected, quantitative data analysed, and qualitative data assessed for recurring themes.
RESULTS: Responses were received from 209 healthcare workers from 53 countries, including 28% from Europe, 24% from North America, 19% from the Asia Pacific region, 17% from the Middle East and 12% from Latin America. Most respondents were physicians (85%) with physician assistants, physical therapists and nurses/nurse practitioners represented in the sample. The main three specialties represented included rheumatology (40%), endocrinology (22%) and orthopaedics (15%). In terms of the type of patient contact, 33% of respondents conducted telephone consultations and 21% video consultations. Bone mineral density assessment by dual-energy X-ray absorptiometry (DXA) usage was affected with only 29% able to obtain a scan as recommended. The majority of clinicians (60%) had systems in place to identify patients receiving parenteral medication, and 43% of clinicians reported difficulty in arranging appropriate osteoporosis medications during the COVID-19 crisis.
CONCLUSIONS: To conclude through surveying a global sample of osteoporosis healthcare professionals, we have observed an increase in telemedicine consultations, delays in DXA scanning, interrupted supply of medications and reductions in parenteral medication delivery.
COVID-19, Coronavirus, Fracture, Osteoporosis
611-617
Fuggle, Nicholas
9ab0c81a-ac67-41c4-8860-23e0fdb1a900
Singer, Andrea
0aefe63e-d7f8-4720-9323-1e248337f396
Gill, Claire
7c3bff19-929f-48e1-b15a-02389610ffa4
Patel, Ami
37fcd585-68cd-44f3-b770-be3176eb0fd7
Medeiros, Andrea
fdd7f9c7-722c-4e0d-984e-f7e622995846
Mlotek, Anastasia Soulié
a58dd2c7-cd89-44d3-a964-e9ae18c3b5a4
Pierroz, Dominique D.
b19cd2e8-fdbe-4992-bc11-b536abeee614
Halbout, Phillipe
7f766664-1109-466a-b095-93fd563bf2a1
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Reginster, Jean-Yves
db56b103-184d-46e1-9600-f47f7a09a492
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Greenspan, Susan L.
bca80638-bd85-4682-8012-037c880dfd06
April 2021
Fuggle, Nicholas
9ab0c81a-ac67-41c4-8860-23e0fdb1a900
Singer, Andrea
0aefe63e-d7f8-4720-9323-1e248337f396
Gill, Claire
7c3bff19-929f-48e1-b15a-02389610ffa4
Patel, Ami
37fcd585-68cd-44f3-b770-be3176eb0fd7
Medeiros, Andrea
fdd7f9c7-722c-4e0d-984e-f7e622995846
Mlotek, Anastasia Soulié
a58dd2c7-cd89-44d3-a964-e9ae18c3b5a4
Pierroz, Dominique D.
b19cd2e8-fdbe-4992-bc11-b536abeee614
Halbout, Phillipe
7f766664-1109-466a-b095-93fd563bf2a1
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Reginster, Jean-Yves
db56b103-184d-46e1-9600-f47f7a09a492
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Greenspan, Susan L.
bca80638-bd85-4682-8012-037c880dfd06
Fuggle, Nicholas, Singer, Andrea, Gill, Claire, Patel, Ami, Medeiros, Andrea, Mlotek, Anastasia Soulié, Pierroz, Dominique D., Halbout, Phillipe, Harvey, Nicholas, Reginster, Jean-Yves, Cooper, Cyrus and Greenspan, Susan L.
(2021)
How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey.
Osteoporosis International, 32 (4), .
(doi:10.1007/s00198-020-05793-3).
Abstract
The effects of COVID-19 have the potential to impact on the management of chronic diseases including osteoporosis. A global survey has demonstrated that these impacts include an increase in telemedicine consultations, delays in DXA scanning, interruptions in the supply of medications and reductions in parenteral medication delivery.
INTRODUCTION: The COVID-19 pandemic has had profound effects on the health of the global population both directly, via the sequelae of the infection, and indirectly, including the relative neglect of chronic disease management. Together the International Osteoporosis Foundation and National Osteoporosis Foundation sought to ascertain the impact on osteoporosis management.
METHODS: Questionnaires were electronically circulated to a sample of members of both learned bodies and included information regarding the location and specialty of respondents, current extent of face to face consultations, alterations in osteoporosis risk assessment, telemedicine experience, alterations to medication ascertainment and delivery and electronic health record (EHR) utilisation. Responses were collected, quantitative data analysed, and qualitative data assessed for recurring themes.
RESULTS: Responses were received from 209 healthcare workers from 53 countries, including 28% from Europe, 24% from North America, 19% from the Asia Pacific region, 17% from the Middle East and 12% from Latin America. Most respondents were physicians (85%) with physician assistants, physical therapists and nurses/nurse practitioners represented in the sample. The main three specialties represented included rheumatology (40%), endocrinology (22%) and orthopaedics (15%). In terms of the type of patient contact, 33% of respondents conducted telephone consultations and 21% video consultations. Bone mineral density assessment by dual-energy X-ray absorptiometry (DXA) usage was affected with only 29% able to obtain a scan as recommended. The majority of clinicians (60%) had systems in place to identify patients receiving parenteral medication, and 43% of clinicians reported difficulty in arranging appropriate osteoporosis medications during the COVID-19 crisis.
CONCLUSIONS: To conclude through surveying a global sample of osteoporosis healthcare professionals, we have observed an increase in telemedicine consultations, delays in DXA scanning, interrupted supply of medications and reductions in parenteral medication delivery.
Text
COVID-19 clinician survey manuscript 20_12_01 (clean)
- Accepted Manuscript
Text
How has COVID-19 affected the treatment of osteoporosis
- Version of Record
More information
Accepted/In Press date: 9 December 2020
e-pub ahead of print date: 8 February 2021
Published date: April 2021
Keywords:
COVID-19, Coronavirus, Fracture, Osteoporosis
Identifiers
Local EPrints ID: 447039
URI: http://eprints.soton.ac.uk/id/eprint/447039
ISSN: 0937-941X
PURE UUID: 5cb2e780-9625-4ee8-aedc-8483e15999f6
Catalogue record
Date deposited: 02 Mar 2021 17:31
Last modified: 18 Mar 2024 03:49
Export record
Altmetrics
Contributors
Author:
Andrea Singer
Author:
Claire Gill
Author:
Ami Patel
Author:
Andrea Medeiros
Author:
Anastasia Soulié Mlotek
Author:
Dominique D. Pierroz
Author:
Phillipe Halbout
Author:
Jean-Yves Reginster
Author:
Susan L. Greenspan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics